<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02865928</url>
  </required_header>
  <id_info>
    <org_study_id>Northwell</org_study_id>
    <nct_id>NCT02865928</nct_id>
  </id_info>
  <brief_title>Serratus Plane Block for Postoperative Pain Control</brief_title>
  <official_title>Serratus Plane Block for Postoperative Pain Control After Breast Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blinded, placebo-controlled trial of serratus plane blocks in
      subjects undergoing outpatient unilateral or bilateral breast surgery. Ninety subjects will
      be enrolled into the study at presurgical testing. Subjects will be stratified based on
      surgery type and randomized to receive a serratus plane block with either bupivicaine HCL or
      placebo. All patients will receive standard intraoperative anesthesia and standard
      postoperative pain control. The primary endpoint is the amount of opioid administered
      postoperatively. Secondary endpoints include postoperative pain intensity at timed intervals,
      amount of opioid administered intraoperatively and postoperatively, incidence of nausea and
      vomiting, time to discharge and patient satisfaction
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 5, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative opioid requirements</measure>
    <time_frame>4 to 10 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain with Numeric Rating Scale</measure>
    <time_frame>4 to 10 hours</time_frame>
    <description>Pain assessed at timed intervals at rest and movement during postoperative period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of postoperative nausea and vomiting</measure>
    <time_frame>4 to 10 hours</time_frame>
    <description>Nausea assessed at time intervals with numeric rating scale and episodes of vomiting and retching recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of antiemetic use</measure>
    <time_frame>4 to 10 hours</time_frame>
    <description>The proportion of patients who required antiemetics during the postoperative period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PACU length of stay</measure>
    <time_frame>4 to 10 hours</time_frame>
    <description>Time to PACU discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction with Likert scale</measure>
    <time_frame>1 week</time_frame>
    <description>Patient satisfaction with pain management</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Outpatient Breast Surgery</condition>
  <condition>Mastopexy</condition>
  <condition>Augmentation</condition>
  <condition>Revision</condition>
  <arm_group>
    <arm_group_label>Bupivicaine HCl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ultrasound guided serratus plane block with bupivacaine HCl.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo injection on operated side, same technique as experimental group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivicaine HCl</intervention_name>
    <description>Ultrasound guided serratus plane block with bupivicaine</description>
    <arm_group_label>Bupivicaine HCl</arm_group_label>
    <other_name>Bupivicaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Same injection technique as intervention arm with normal saline</description>
    <arm_group_label>Normal Saline</arm_group_label>
    <other_name>0.09% NaCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA I-III.

          -  Undergoing outpatient breast surgery requiring general anesthesia, including but not
             limited to mastectomy, lumpectomy, reconstruction with tissue expanders or implants
             and reconstruction revision.

        Exclusion Criteria:

          -  Unable to provide informed consent.

          -  Patients who are pregnant or nursing.

          -  ASA IV-V.

          -  Alcohol or narcotic dependence in the last 2 years.

          -  Concurrent condition requiring regular use of analgesia that may confound
             post-surgical assessments as determined by principle investigator.

          -  Hepatic disease.

          -  Allergies to amide anesthetics as determined from medical history or patient
             self-report.

          -  Evidence of infection at injection site.

          -  Contraindication to pain medications such as acetominophen, morphine, oxycodone,
             keterolac, dilaudid, Toradol.

          -  Body weight &lt;50kg.

          -  BMI&gt;40kg/m2.

          -  History of hypotension.

          -  Abnormal renal (creatinine &gt; 1.5 mg/dL) function.

          -  Heart block.

          -  Any physical, mental or medical condition, that in the opinion of the investigator,
             makes study participation inadvisable.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith Aronsohn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwell Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oonagh Dowling, PhD</last_name>
    <phone>718-470-7630</phone>
    <email>odowling@northwell.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Northwell Health System</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Aronsohn, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Oonagh Dowling, PhD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2016</study_first_submitted>
  <study_first_submitted_qc>August 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2016</study_first_posted>
  <last_update_submitted>September 5, 2017</last_update_submitted>
  <last_update_submitted_qc>September 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwell Health</investigator_affiliation>
    <investigator_full_name>Judith Aronsohn</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

